Medical treatment

A real-life analysis of anti-atherosclerotic medical treatment and risk factor control in a cohort of vascular surgery patients

This article was originally published here

Port Acta Med. 2022 Feb 9. doi: 10.20344/amp.16458. Online ahead of print.

ABSTRACT

Introduction: The aim of this study was to evaluate the pattern of taking anti-atherosclerosis drugs in patients admitted to a vascular surgery department, the effective control of target values ​​and its subsequent modification by the vascular surgery team.

Material and methods: A retrospective monocentric cohort study of prospectively collected data was carried out between May 2017 and May 2018 in a tertiary center. STROBE guidelines were followed. All patients undergoing primary elective surgery for carotid disease, aortic aneurysm and peripheral arterial disease were included. The “best medical treatment” was defined as a treatment comprising both antithrombotic and lipid-lowering treatment and, where appropriate, antihypertensive and antidiabetic drugs. The best basic and post-discharge medical treatments have been recorded. A blood workup was performed on admission and a “sufficiently controlled patient” was defined if all blood test values ​​were within guidelines.

RESULTS: A total of 279 patients (78% men; mean age 69 years) were included. Optimal medical treatment was recorded in 58.8% at admission, but improved to 73.8% (95% CI, 2.197, 7.781; p

CONCLUSION: In our current practice, only 75% of patients receive the best medical treatment. Although admission to a vascular surgery unit was an opportunity to optimize medical treatment, treatment remains suboptimal in a quarter of patients. Further efforts should be made to alert vascular surgeons to this problem and to find future multidisciplinary solutions that may improve the cardiovascular risk profiles of these patients.

PMID:35139009 | DOI: 10.20344/amp.16458